Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Star Scientific IND Blocks Supplement Marketing Options – FDA

This article was originally published in The Tan Sheet

Executive Summary

An FDA warning letter deems Star Scientific’s CigRx and Anatabloc supplements unapproved drugs due to multiple issues, including claims. The firm’s approved IND study for the ingredient also prevents its use in supplements, the agency says.

Advertisement

Related Content

Industry News Roundup
Industry News Roundup
Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation
Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation
In Brief: Advertising Regulation, Vansen Consumer, Star Scientific
In Brief: Advertising Regulation, Vansen Consumer, Star Scientific
In Brief: laxatives warning, FTC settlement, ChromaDex inks 5LINX deal
In Brief: laxatives warning, FTC settlement, ChromaDex inks 5LINX deal
Ovos' Former IND Homotaurine Strikes Out As Dietary Ingredient
FDA's Tobacco Center To Mull First Modified-Risk Claim Application

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel